Oral Presentation: OP16: A randomised, multicentre, double-blind, placebo-controlled study of a targeted release oral cyclosporine formulation in the treatment of mild to moderate ulcerative colitis: efficacy resultsScientific Programme 2019
Oral Presentation: OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsiesScientific Programme 2019
Oral Presentation: OP19: Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve ulcerative colitisScientific Programme 2019
Oral Presentation: OP20: Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s DiseaseScientific Programme 2019
Oral Presentation: OP21: ABX464 is safe and efficacious in a proof of concept study in ulcerative colitis patientsScientific Programme 2019
Oral Presentation: OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis in various animal modelsScientific Programme 2019
Oral Presentation: OP24: Effectiveness and safety of ustekinumab 90 mg every four weeks in Crohn's diseaseScientific Programme 2019
Oral Presentation: OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s diseaseScientific Programme 2019
Oral Presentation: OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: Final results from the GEMINI LTS studyScientific Programme 2019
Oral Presentation: OP29: ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancerScientific Programme 2019
Oral Presentation: OP30: Serum proteomic profiling predicts and diagnoses pouchitis in ulcerative colitis patients undergoing ileal pouch-anal anastomosisScientific Programme 2019
Oral Presentation: OP34: VARSITY: A Double-Blind, Double-Dummy, Randomised, Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative ColitisScientific Programme 2019
Oral Presentation: OP37: Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFIScientific Programme 2019
Oral Presentation: OP38: Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitisScientific Programme 2019
Outcomes from the ECCO Fellowship 2018: Monocyte-derived macrophages as crucial players in the resolution of inflammation and tissue repair in Inflammatory Bowel DiseaseScientific Programme 2019
Outcomes from the ECCO Fellowship 2018: Role of TNF-inducible gene-6 (TSG-6) in fistulising Crohn's DiseaseScientific Programme 2019
Outcomes from the ECCO Pioneer Award 2017: Faecal transplantation using a novel conditioning method for donor and recipient in mild to moderate treatment refractory colitis in Inflammatory Bowel DiseaseScientific Programme 2019